Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,075 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Profile of the multicenter cohort of the German Cancer Consortium's Clinical Communication Platform.
Maier D, Vehreschild JJ, Uhl B, Meyer S, Berger-Thürmel K, Boerries M, Braren R, Grünwald V, Hadaschik B, Palm S, Singer S, Stuschke M, Juárez D, Delpy P, Lambarki M, Hummel M, Engels C, Andreas S, Gökbuget N, Ihrig K, Burock S, Keune D, Eggert A, Keilholz U, Schulz H, Büttner D, Löck S, Krause M, Esins M, Ressing F, Schuler M, Brandts C, Brucker DP, Husmann G, Oellerich T, Metzger P, Voigt F, Illert AL, Theobald M, Kindler T, Sudhof U, Reckmann A, Schwinghammer F, Nasseh D, Weichert W, von Bergwelt-Baildon M, Bitzer M, Malek N, Öner Ö, Schulze-Osthoff K, Bartels S, Haier J, Ammann R, Schmidt AF, Guenther B, Janning M, Kasper B, Loges S, Stilgenbauer S, Kuhn P, Tausch E, Runow S, Kerscher A, Neumann M, Breu M, Lablans M, Serve H. Maier D, et al. Among authors: schuler m. Eur J Epidemiol. 2023 May;38(5):573-586. doi: 10.1007/s10654-023-00990-w. Epub 2023 Apr 5. Eur J Epidemiol. 2023. PMID: 37017830 Free PMC article.
German Cancer Consortium (DKTK) - A national consortium for translational cancer research.
Joos S, Nettelbeck DM, Reil-Held A, Engelmann K, Moosmann A, Eggert A, Hiddemann W, Krause M, Peters C, Schuler M, Schulze-Osthoff K, Serve H, Wick W, Puchta J, Baumann M. Joos S, et al. Among authors: schuler m. Mol Oncol. 2019 Mar;13(3):535-542. doi: 10.1002/1878-0261.12430. Epub 2019 Jan 9. Mol Oncol. 2019. PMID: 30561127 Free PMC article. Review.
Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial.
Guberina M, Eberhardt W, Stuschke M, Gauler T, Aigner C, Schuler M, Stamatis G, Theegarten D, Jentzen W, Herrmann K, Pöttgen C. Guberina M, et al. Among authors: schuler m. Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1439-1447. doi: 10.1007/s00259-019-4270-x. Epub 2019 Feb 1. Eur J Nucl Med Mol Imaging. 2019. PMID: 30710323 Clinical Trial.
ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy.
Guberina M, Sak A, Pöttgen C, Tinhofer-Keilholz I, Budach V, Balermpas P, Von der Grün J, Rödel CM, Gkika E, Grosu AL, Abdollahi A, Debus J, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, De-Colle C, Welz S, Linge A, Lohaus F, Baretton G, Gauler T, Baumann M, Krause M, Schuler M, Bankfalvi A, Höing B, Lang S, Stuschke M. Guberina M, et al. Among authors: schuler m. Pharmacogenomics J. 2021 Feb;21(1):37-46. doi: 10.1038/s41397-020-0174-1. Epub 2020 Jun 16. Pharmacogenomics J. 2021. PMID: 32546699 Free PMC article.
Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
Wiesweg M, Mairinger F, Reis H, Goetz M, Kollmeier J, Misch D, Stephan-Falkenau S, Mairinger T, Walter RFH, Hager T, Metzenmacher M, Eberhardt WEE, Zaun G, Köster J, Stuschke M, Aigner C, Darwiche K, Schmid KW, Rahmann S, Schuler M. Wiesweg M, et al. Among authors: schuler m. Eur J Cancer. 2020 Nov;140:76-85. doi: 10.1016/j.ejca.2020.09.015. Epub 2020 Oct 12. Eur J Cancer. 2020. PMID: 33059196
Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V600-mutated Squamous Cell Lung Cancer: Concurrent Evolvement of PTEN and MEK1 Mutations.
Metzenmacher M, Goetz M, Herold T, Stuschke M, Aigner C, Darwiche K, Eberhardt WE, Schuler M, Wiesweg M. Metzenmacher M, et al. Among authors: schuler m. Clin Lung Cancer. 2021 Sep;22(5):e668-e672. doi: 10.1016/j.cllc.2020.11.008. Epub 2020 Dec 2. Clin Lung Cancer. 2021. PMID: 33551244 No abstract available.
BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy.
Wiesweg M, Preuß C, Roeper J, Metzenmacher M, Eberhardt W, Stropiep U, Wedeken K, Reis H, Herold T, Darwiche K, Aigner C, Stuschke M, Schildhaus HU, Schmid KW, Falk M, Heukamp L, Tiemann M, Griesinger F, Schuler M. Wiesweg M, et al. Among authors: schuler m. Eur J Cancer. 2021 May;149:211-221. doi: 10.1016/j.ejca.2021.02.036. Epub 2021 Apr 16. Eur J Cancer. 2021. PMID: 33872981
1,075 results